نتائج البحث - "Akewanlop C"

1

دورية أكاديمية

OA01.09 Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB–IIIA Non-Small Cell Lung Cancer: Updated ADAURA Results

المؤلفون: Herbst, R.S., Wu, Y.-L., Grohe, C., John, T., Majem, M., Wang, J., Kato, T., Goldman, J.W., Kim, S.-W., Yu, C.-J., Vu, H.V., Mukhametshina, G., Akewanlop, C., de Marinis, F., Shepherd, F.A., Urban, D., Stachowiak, M., Bolanos, A., Huang, X., Tsuboi, M.

المصدر: Journal of Thoracic Oncology ; volume 18, issue 3, page e4 ; ISSN 1556-0864

مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Oncology

الإتاحة: https://doi.org/10.1016/j.jtho.2022.09.125Test
https://api.elsevier.com/content/article/PII:S1556086422017117?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1556086422017117?httpAccept=text/plainTest

View record in BASE

2

دورية أكاديمية

Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.

المؤلفون: Wu, Y-L, John, T, Grohe, C, Majem, M, Goldman, JW, Kim, S-W, Kato, T, Laktionov, K, Vu, HV, Wang, Z, Lu, S, Lee, KY, Akewanlop, C, Yu, C-J, de Marinis, F, Bonanno, L, Domine, M, Shepherd, FA, Zeng, L, Atasoy, A, Herbst, RS, Tsuboi, M

العلاقة: pii: S1556-0864(21)03285-8; Wu, Y. -L., John, T., Grohe, C., Majem, M., Goldman, J. W., Kim, S. -W., Kato, T., Laktionov, K., Vu, H. V., Wang, Z., Lu, S., Lee, K. Y., Akewanlop, C., Yu, C. -J., de Marinis, F., Bonanno, L., Domine, M., Shepherd, F. A., Zeng, L. ,. Tsuboi, M. (2022). Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. J Thorac Oncol, 17 (3), pp.423-433. https://doi.org/10.1016/j.jtho.2021.10.014Test.; http://hdl.handle.net/11343/308993Test

الإتاحة: https://doi.org/10.1016/j.jtho.2021.10.014Test
http://hdl.handle.net/11343/308993Test

View record in BASE

النص الكامل

3

دورية أكاديمية

المؤلفون: Majem, M, Goldman, JW, John, T, Grohe, C, Laktionov, K, Kim, S-W, Kato, T, Vu, HV, Lu, S, Li, S, Lee, KY, Akewanlop, C, Yu, C-J, de Marinis, F, Bonanno, L, Domine, M, Shepherd, FA, Atagi, S, Zeng, L, Kulkarni, D, Medic, N, Tsuboi, M, Herbst, RS, Wu, Y-L

العلاقة: pii: 1078-0432.CCR-21-3530; Majem, M., Goldman, J. W., John, T., Grohe, C., Laktionov, K., Kim, S. -W., Kato, T., Vu, H. V., Lu, S., Li, S., Lee, K. Y., Akewanlop, C., Yu, C. -J., de Marinis, F., Bonanno, L., Domine, M., Shepherd, F. A., Atagi, S., Zeng, L. ,. Wu, Y. -L. (2022). Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. CLINICAL CANCER RESEARCH, 28 (11), pp.2286-2296. https://doi.org/10.1158/1078-0432.CCR-21-3530Test.; http://hdl.handle.net/11343/320368Test

الإتاحة: https://doi.org/10.1158/1078-0432.CCR-21-3530Test
http://hdl.handle.net/11343/320368Test

View record in BASE

النص الكامل

4

دورية أكاديمية

296P Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA

المؤلفون: Wu, Y-L., Tsuboi, M., Grohe, C., John, T., Majem Tarruella, M., Wang, J., Kato, T., Goldman, J.W., Kim, S-W., Yu, C-J., Vinh Vu, H., Mukhametshina, G., Akewanlop, C., de Marinis, F., Shepherd, F.A., Urban, D., Stachowiak, M., Bolanos, A., Huang, X., Herbst, R.S.

المساهمون: AstraZeneca

المصدر: Annals of Oncology ; volume 33, page S1548-S1549 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2022.10.324Test
https://api.elsevier.com/content/article/PII:S092375342204515X?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S092375342204515X?httpAccept=text/plainTest

View record in BASE

5

دورية أكاديمية

LBA47 Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA

المؤلفون: Tsuboi, M., Wu, Y-L., Grohe, C., John, T., Tarruella, M. Majem, Wang, J., Kato, T., Goldman, J.W., Kim, S-W., Yu, C-J., Vu, H. Vinh, Mukhametshina, G., Akewanlop, C., de Marinis, F., Shepherd, F.A., Urban, D., Stachowiak, M., Bolanos, A.L., Huang, X., Herbst, R.S.

المساهمون: AstraZeneca

المصدر: Annals of Oncology ; volume 33, page S1413-S1414 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2022.08.047Test
https://api.elsevier.com/content/article/PII:S0923753422039254?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753422039254?httpAccept=text/plainTest

View record in BASE

6

دورية أكاديمية

EE3 Cost-Utility Analysis of Xelox Plus Bevacizumab Versus Xelox for Metastatic Colorectal Cancer Treatment in Thailand

المؤلفون: Wanitphisitphan, C, Kositamongkol, C, Korphaisarn, K, Akewanlop, C, Srimuninnimit, V, Phisalprapa, P

المصدر: Value in Health ; volume 25, issue 12, page S53 ; ISSN 1098-3015

مصطلحات موضوعية: Public Health, Environmental and Occupational Health, Health Policy

الإتاحة: https://doi.org/10.1016/j.jval.2022.09.258Test
https://api.elsevier.com/content/article/PII:S1098301522024627?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1098301522024627?httpAccept=text/plainTest

View record in BASE

7

دورية أكاديمية

A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer.

المؤلفون: Wu, Y-L, Tsuboi, M, John, T, Grohe, C, Majem, M, Goldman, JW, Laktionov, K, Kim, S-W, Kato, T, Vu, H-V, Lu, S, Lee, K-Y, Akewanlop, C, Yu, C-J, de Marinis, F, Bonanno, L, Domine, M, Shepherd, FA, Zeng, L, Hodge, R, Atasoy, A, Rukazenkov, Y, Herbst, RS

العلاقة: Wu, Y. -L., Tsuboi, M., John, T., Grohe, C., Majem, M., Goldman, J. W., Laktionov, K., Kim, S. -W., Kato, T., Vu, H. -V., Lu, S., Lee, K. -Y., Akewanlop, C., Yu, C. -J., de Marinis, F., Bonanno, L., Domine, M., Shepherd, F. A., Zeng, L. ,. Herbst, R. S. (2021). A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer. Future Oncol, 17 (35), pp.4827-4835. https://doi.org/10.2217/fon-2021-0752Test.; http://hdl.handle.net/11343/310010Test

الإتاحة: https://doi.org/10.2217/fon-2021-0752Test
http://hdl.handle.net/11343/310010Test

View record in BASE